Janssen Therapeutics
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(800) 526-7736Website
www.symtuzahcp.comRevenue
$7.2 MillionIndustry
About Janssen Therapeutics
SYMTUZA offers a single-tablet regimen combining darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1. The product is designed for both treatment-naïve and treatment-experienced patients, emphasizing sustained tolerability and proven efficacy. The company provides resources for healthcare professionals and patients, including prescribing information and support for treatment decisions. SYMTUZA aims to simplify antiretroviral therapy and improve patient satisfaction while addressing safety and tolerability concerns.Explore more
SIC Code 28,283NAICS Code 32,325Show more
Janssen Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Janssen Therapeutics
Compare insights from companies similar to Janssen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Janssen Therapeutics Tech Stack
A closer look at the technologies used by Janssen Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Janssen Therapeutics
Sign Up For FreeTo access detailed company insights
SYMTUZA offers a single-tablet regimen combining darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1. The product is designed for both treatment-naïve and treatment-experienced patients, emphasizing sustained tolerability and proven efficacy. The company provides resources for healthcare professionals and pati... Read More
